HeartBeam Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Rob Eno

Algemeen directeur

US$2.6m

Totale compensatie

Percentage CEO-salaris	13.5%
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	1.4yrs

Recente managementupdates

Recent updates

HeartBeam gets patent to enable generation of its credit card-sized ECG, shares rise ~15%

Sep 28

HeartBeam surges 54% on U.S. patent for ECG patch monitor to detect heart attacks

Sep 15

HeartBeam GAAP EPS of $0.43 beats by $0.70

Aug 11

HeartBeam: Cardiovascular Diagnostics On The Go

Dec 14

Analyse CEO-vergoeding

Hoe is Rob Eno's beloning veranderd ten opzichte van HeartBeam's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$18m
Jun 30 2024	n/a	n/a	-US$17m
Mar 31 2024	n/a	n/a	-US$15m
Dec 31 2023	US$3m	US$345k	-US$15m

Compensatie versus markt: De totale vergoeding ($USD 2.55M ) Rob } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 647.72K ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Rob te vergelijken met de prestaties van het bedrijf.

CEO

Rob Eno

less than a year

Tenure

US$2,552,204

Compensatie

Mr. Robert P. Eno, also known as Rob, is Chief Executive Officer of HeartBeam, Inc. since October 21, 2024 and serves as its Chief Business Officer and was President from January 18, 2023 to October 21, 20...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Richard Ferrari	Executive Chairman	5.8yrs	US$238.59k	0.64% $ 477.5k
Robert Eno	CEO & Chief Business Officer	less than a year	US$2.55m	geen gegevens
Branislav Vajdic	Founder	less than a year	US$3.25m	3.42% $ 2.5m
Kenneth Persen	Chief Technology Officer	2.3yrs	US$1.41m	0% $ 0
Timothy Cruickshank	Chief Financial Officer	less than a year	geen gegevens	geen gegevens
Peter J. Fitzgerald	Member of Scientific Advisory Board & Chief Medical Officer	2.1yrs	geen gegevens	geen gegevens
Richa Gujarati	Senior Vice President of Product	1.2yrs	geen gegevens	geen gegevens

0.7yrs

Gemiddelde duur

68yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van BEAT wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.7 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Richard Ferrari	Executive Chairman	5.8yrs	US$238.59k	0.64% $ 477.5k
Branislav Vajdic	Founder	no data	US$3.25m	3.42% $ 2.5m
Peter J. Fitzgerald	Member of Scientific Advisory Board & Chief Medical Officer	less than a year	geen gegevens	geen gegevens
Mark Strome	Independent Director	1.4yrs	US$104.72k	1.03% $ 764.4k
George De Urioste	Independent Director	no data	US$152.50k	0.090% $ 66.9k
Michael Jaff	Independent Director	1.3yrs	US$148.65k	0.052% $ 39.0k
Willem Elfrink	Independent Director	no data	US$140.64k	1.47% $ 1.1m
Robert Harrington	Member of Scientific Advisory Board	less than a year	geen gegevens	geen gegevens
Marga Ortigas-Wedekind	Independent Director	no data	US$140.00k	0.36% $ 267.6k
C. Gibson	Chairman of Scientific Advisory Board	2.8yrs	geen gegevens	geen gegevens
Kenneth Nelson	Independent Director	1.4yrs	US$102.60k	0.35% $ 262.2k
Tony Das	Member of Scientific Advisory Board	less than a year	geen gegevens	geen gegevens

1.4yrs

Gemiddelde duur

66.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van BEAT wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.4 jaar), wat duidt op een nieuw bestuur.

HeartBeam Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

Heartbeam Announces Chief Executive Officer Changes, Effective October 21, 2024

HeartBeam, Inc. Appoints Timothy Cruickshank as Chief Financial Officer

HeartBeam, Inc., Annual General Meeting, Jun 12, 2024

High number of new and inexperienced directors

High number of new and inexperienced directors

HeartBeam, Inc. Announces Retirement of Richard Brounstein as Chief Financial Officer

Recent updates

Heartbeam, Inc. Announces Positive Data from Two Studies At Prestigious American Heart Association Conference

New minor risk - Share price stability

HeartBeam, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Heartbeam Announces Chief Executive Officer Changes, Effective October 21, 2024

Here's Why We're Watching HeartBeam's (NASDAQ:BEAT) Cash Burn Situation

HeartBeam, Inc. Appoints Timothy Cruickshank as Chief Financial Officer

New major risk - Financial position

HeartBeam, Inc. to Report Q2, 2024 Results on Aug 14, 2024

Price target decreased by 38% to US$5.00

HeartBeam, Inc. has filed a Follow-on Equity Offering in the amount of $17 million.

HeartBeam, Inc., Annual General Meeting, Jun 12, 2024

HeartBeam, Inc. to Report Q1, 2024 Results on May 09, 2024

Price target decreased by 38% to US$5.00

High number of new and inexperienced directors

HeartBeam, Inc. Presents Positive Results on its Artificial Intelligence Capabilities for Detecting Arrhythmias

New major risk - Revenue and earnings growth

High number of new and inexperienced directors

HeartBeam, Inc. Announces First Patients Enrolled in Pivotal Study Evaluating HeartBeam's AIMIGo System for Synthesizing A 12-Lead ECG

HeartBeam, Inc. Receives Two New US Patents for Its Core Cardiac Monitoring Technology

HeartBeam, Inc. to Report Q4, 2023 Results on Mar 20, 2024

HeartBeam, Inc. Announces Retirement of Richard Brounstein as Chief Financial Officer

HeartBeam, Inc. Unveils AI Program Designed to Deliver Unprecedented Personalized Cardiac Insights

HeartBeam, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Heartbeam, Inc. Appoints Richa Gujarati as Senior Vice President, Product

HeartBeam, Inc. Appoints Michael R. Jaff to the Board of Directors

Less than half of directors are independent

Heartbeam Appoints Ken Nelson and Mark Strome to the Board of Directors

HeartBeam, Inc., Annual General Meeting, Jul 07, 2023

HeartBeam, Inc. Announces Automated Cardiac Detection Patent Granted for Heartbeam Aimigo™ System

HeartBeam, Inc. to Report Q1, 2023 Results on May 11, 2023

No longer forecast to breakeven

HeartBeam, Inc. Appoints Robert Eno as President

Companies Like HeartBeam (NASDAQ:BEAT) Could Be Quite Risky

HeartBeam Receives European Patent for Signal Transformation from Vector Electrocardiogram (VECG) to 12-Lead Electrocardiogram (ECG)

HeartBeam, Inc. Announces Patent for 12-Lead Electrocardiogram Smartwatch-Based Monitor

Less than half of directors are independent

HeartBeam, Inc. to Report Q3, 2022 Results on Nov 10, 2022

HeartBeam Names Peter J. Fitzgerald, MD, PhD, as Chief Medical Officer

HeartBeam gets a new chief medical officer

HeartBeam Broadens Product Portfolio Pipeline with Smartwatch Connectivity Enablement for 24/7 Heart Monitoring Solution

Heartbeam Grants Patent for Signal Transformation from Vector Electrocardiogram (VECG) to 12-Lead Electrocardiogram (ECG)

HeartBeam gets patent to enable generation of its credit card-sized ECG, shares rise ~15%

HeartBeam surges 54% on U.S. patent for ECG patch monitor to detect heart attacks

Heartbeam Announces FDA Submission of Heartbeam Aimi™ Product

Heartbeam, Inc. Announces Resignation of Alan Baumel as Chief Operating Officer, Effective on August 15, 2022

HeartBeam GAAP EPS of $0.43 beats by $0.70

HeartBeam, Inc. Announces the Appointment of Ken Persen to the Role of Chief Technology Officer

HeartBeam, Inc. to Report Q2, 2022 Results on Aug 11, 2022

HeartBeam, Inc., Annual General Meeting, Jun 15, 2022

No independent directors

HeartBeam, Inc. Announces Board Changes

HeartBeam: Cardiovascular Diagnostics On The Go

Director exercised options to buy US$1.4m worth of stock.

No independent directors

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd